Resources

To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database

Results

showing 1-10 of 1050

ARV-Based and Multipurpose Prevention Technology R&D Pipeline

The pipeline of non-vaccine HIV prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable antiretrovirals and more. Also pictured are the range of MPTs in development that aim to reduce the risk of HIV and STIs and/or provide effective contraception for women.

Prevention Option:

September 2026


At A Glance: The MPT R&D Pipeline

This graphic shows the status of products in development.

September 2026


Lenacapavir Regulatory Approval

Regulatory approvals, pending decisions, and appeals as of September 2026.

Prevention Option:

September 2026


HIV Prevention Pipeline: Products to Watch

From the People’s Research Agenda, this graphic tracks the pipeline of potential new HIV prevention options across broadly neutralizing antibodies, preventive vaccines, pre-exposure prophylaxis, and multipurpose technologies.

September 2026


Aftershocks Roundtable: How do we rebuild our HIV and public health infrastructure?

Please join TCA and IAPAC’s Dr. José M. Zuniga – author of the new book “Aftershocks: Trump 2.0, Public Health, and Our Better Angels” – and a dynamic panel to discuss the profound disruption of public health systems over the past almost...

October 28, 2026


AVAC’s Remarks to the NIAID Council and the ARAC on the proposed NIAID reorganization

AVAC delivered a public comment for the record at the NIAID Council meeting raising concerns about the proposed NIAID reorganization and its potential impact on HIV research, including the elimination of the Division of Clinical Research, disruption...

September 2026


Reaching Key Populations with Long-Acting PrEP: The launch of the PrEP Power Demand Generation Toolkit

The need for PrEP amongst key populations (KPs) is high yet KPs remain underserved in many PrEP programs. To help address this need, Global Black Gay Men Connect, Access Bridge, and AVAC, alongside local partners in Eswatini, Kenya, and Zambia,...

Prevention Option:

October 14, 2026


Artificial Intelligence in the HIV response: All the good stuff from AIDS2026

An analysis by Jirair Ratevosian of the Duke Global Health Institute looked comprehensively at AI-related abstracts, key themes from use cases, and emerging trends at AIDS 2026. His review shows the potential of AI to support HIV testing and prevention, including PrEP, and improve linkages to care and services, particularly in sub-Saharan Africa. “AI is becoming a new front door to HIV services,” he writes, but the analysis also shows that while most of the research was focused on feasibility and pilot implementation of AI, a significant evidence gap around health outcomes, as well as privacy, community engagement, and governance remains. He concludes that: AI is working, but trust is what makes or breaks the product; specialized tools beat generics; human-in-the-loop is becoming standard; the field needs to move from pilots to proof of outcomes; and scale depends on systems, not just models.

September 2026


AVAC Comment on Proposed Reorganization of the National Institutes of Allergy and Infectious Diseases (NIAID)

In response to the National Institute of Health’s (NIH) proposed reorganization of the National Institutes of Allergy and Infectious Diseases (NIAID), AVAC submitted comment to the Office of the Director of the NIH. Citing concerns of dismantling a currently unified trial oversight and support system, disruptions to trial site readiness and impacts on community engagement, and delays in funding and clinical trials, AVAC urged NIH leadership to meaningfully consider the recommendations of AVAC and many allied public health partners on the proposed restructuring.

September 2026


Combo bNAbs for HIV Prevention – Latest Developments

Please join AVAC for a global webinar: Combo bNAbs for HIV Prevention – Latest Developments. Broadly neutralizing antibodies (bNAbs) remain at the center of research toward an HIV vaccine and immune-based HIV prevention. In particular, researchers...

September 30, 2026


showing 1-10 of 1050